Zai Lab Limited (ZLAB) News

Zai Lab Limited (ZLAB): $37.07

0.47 (+1.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ZLAB to Watchlist
Sign Up

Industry: China


Ranked

of 42

in industry

Filter ZLAB News Items

ZLAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ZLAB News Highlights

  • ZLAB's 30 day story count now stands at 4.
  • Over the past 9 days, the trend for ZLAB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ZLAB are LAB, ADC and DRUG.

Latest ZLAB News From Around the Web

Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.

Latest Push by Chinese Firms to Avoid Delistings Falls Short

(Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark

Yahoo | September 29, 2022

Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment

Seagen Inc (NASDAQ: SGEN) and Zai Lab Limited (NASDAQ: ZLAB) have announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. TIVDAK is the first and only ADC approved in the U.S. for treating adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The collaboration supports regional patient enrollment for InnovaTV 301

Yahoo | September 27, 2022

Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab will Leverage its Leadership in Women’s Cancer in China to Commercialize and Expand Patient Access to TIVDAK -- -- Collaboration Supports Regional Patient Enrollment for InnovaTV 301, a Global Phase 3 Trial of TIVDAK in Patients with Recurrent or Metastatic Cervical Cancer -- SHANGHAI and CAMBRIDGE, Ma

Yahoo | September 27, 2022

Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting

New subgroup analysis of the Phase 3 PRIME study reveals improvement in efficacy outcomes for ZEJULA® (niraparib) maintenance treatment when started within 12 weeks after first-line platinum-based chemotherapy (1LCT)SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will present a poster featuring initiation timing analysis from the Phase

Yahoo | September 20, 2022

“A Strong Power in Rapid Ascent”: 10 China Stocks in Ray Dalio’s Portfolio

In this article, we discuss 10 China stocks in Ray Dalio’s portfolio. If you want to skip our analysis of Dalio’s stance on China, go directly to 5 China Stocks in Ray Dalio’s Portfolio. Ray Dalio, the billionaire chief of Bridgewater Associates, shared his thoughts on China in a series of tweets on August 31. […]

Yahoo | September 2, 2022

Zai Lab Announces Participation in September Investor Conferences

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will participate in the following investor conferences in September: 5th HKEX Biotech Summit 2022Panel Discussion: Thursday, September 1, 2022, 3:10 p.m. HKTLocation: Hong Kong Citi’s 17th Annual BioPharma ConferenceFireside Chat: Thursday, Sept

Yahoo | August 23, 2022

Analysts Offer Insights on Healthcare Companies: Novavax (NVAX), Indaptus Therapeutics (INDP) and Zai Lab (ZLAB)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novavax (NVAX – Research Report), Indaptus Therapeutics (INDP – Research Report) and Zai Lab (ZLAB – Research Report) with bullish sentiments. Novavax (NVAX) In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Novavax, with a price target of $126.00. The company's shares closed last Monday at $57.25, close to its 52-week low of $34.88. According to TipRanks.

Brian Anderson on TipRanks | August 9, 2022

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by ZEJULA; strong balance sheet with a cash position of $1.26 billion Company to host a conference call and webcast on August 10, 2022, at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative,

Yahoo | August 9, 2022

Why Earnings Season Could Be Great for Zai Lab (ZLAB)

Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | August 8, 2022

Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and negative symptoms of schizophrenia, as measured by the PANSS positive, PANSS negative and PANSS negative Marder factor subscales KarXT was generally well tolerated, with a side effect profile substantially consistent with prior tr

Yahoo | August 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5493 seconds.